Generic Drug Product Development (ANDA) and Paragraph IV Filing Strategy (Exclusive to the US Market)
June 7, 2013 - Palo Alto CA US

Phone: 650-620-3915
Fax: 650-963-2556

Areas Covered in the Webinar: Strategic Planning for an ANDA vs Paragraph IV Efficient Implementation and Communication with the FDA. Content and Format of ANDA’s Plan for FDA-Sponsor Meetings FDA Expectations and CMC Data including Bioavailability/Bioequivalence Outline of Paragraph IV Applications and Case Studies Who will Benefit: This topic applies to personnel/ companies in the pharma/biopharma industries. The employees who will benefit most include: Senior management Regulatory affairs Quality Assurance CMC and Clinical Development Documentation Scientists, R&D Product Development

More Information

Newsletter Signup
Newsletter Signup
Get the latest channel trends, news, and insights
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.